The University of Cincinnati Cancer Center has been recognized as one of 60 hospitals and health systems in the United States with great oncology programs headed into 2023, according to Becker’s Hospital Review.
The Cancer Center was named alongside 59 programs across the nation known for developing cutting-edge, novel therapies and research that have improved outcomes and access to care for cancer patients. The hospitals and health systems recognized on the list are publicly recognized for improvements in patient care for local patients and on a national level.
“The University of Cincinnati Cancer Center is driven by our quest be on the forefront of the discoveries that are transforming cancer care for southwest Ohio and beyond,” William Barrett, MD, co-director of the University of Cincinnati Cancer Center and Professor and Chair of Radiation Oncology at the University of Cincinnati College of Medicine said. “We are proud of the accomplishments of our nationally recognized cancer center members for the work they have accomplished in minimizing the suffering and mortality associated with this disease.”
“Our tripartite mission of world-class clinical care, research and teaching means we're committed to excellence,” Syed Ahmad, MD, co-director of University of Cincinnati Cancer Center and The Hayden Family Endowed Chair for Cancer Research and Professor of Surgery and Chief of the Division of Surgical Oncology at the University of Cincinnati College of Medicine added. “We are giving hope to patients by moving discoveries from the laboratory to the clinic then into our local communities to educate and fundamentally transform the fight against cancer.”
Formed in January 2020, the University of Cincinnati Cancer Center is a collaboration between the University of Cincinnati, Cincinnati Children’s and UC Health. It includes 10 multidisciplinary disease-based centers that integrate leading-edge research, clinical trials and patient care.
In 2022, the cancer center treated 814 patients in 362 clinical trials. Most recently, the University of Cincinnati Cancer Center has been accepted as a member of the National Cancer Center Institute’s Experimental Therapeutics Clinical Trials Network, an exclusive group of 12 institutions that offer expanded opportunities for patients to enroll in early-stage clinical trials.